Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-stroke Delirium Screening (PSD Screen)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03930719
Recruitment Status : Completed
First Posted : April 29, 2019
Last Update Posted : June 4, 2020
Sponsor:
Information provided by (Responsible Party):
University Medicine Greifswald

Brief Summary:

For a long time, delirium was considered a merely temporary dysfunction of the brain. Today, it is established that it is a brain disease associated with network dysfunction, neuroinflammation and impaired transmitter homeostasis in a multicausal model. Following an episode of delirium, many patients do not return to their prior level of cognitive and functional performance. In particular, failed or delayed diagnosis with consecutive inadequate therapy contribute to the development of long-term cognitive decline that may ultimately lead to long-term care. Stroke patients are a particularly common delirium-affected population (10-46% depending on severity). Despite the frequency and clinical relevance of delirium in stroke patients, diagnostic characteristics of common screening methods are unknown. Similarly, the clinical phenotype and risk factors of patients who develop delirium have not been adequately described.

This study primarily aims to evaluate the diagnostic properties of established screening tools for delirium in a prospective cohort of well-characterised patients following ischemic cerebral events (either transient or manifest stroke). Secondary outcome criteria include predictors of post-stroke delirium (PSD) such as stroke location and size, pre-stroke cognitive functioning, ability to participate in daily routine activities and medical conditions.


Condition or disease Intervention/treatment
Delirium Ischemic Stroke Transient Ischemic Attack Diagnostic Test: Stroke screening tools

Layout table for study information
Study Type : Observational
Actual Enrollment : 141 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Evaluation of Delirium Screening Tools for the Detection of Post-stroke Delirium
Actual Study Start Date : April 22, 2019
Actual Primary Completion Date : July 21, 2019
Actual Study Completion Date : August 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Delirium

Group/Cohort Intervention/treatment
PSD
Patients fulfilling DSM-5 criteria of PSD within 7 days of admission.
Diagnostic Test: Stroke screening tools
Patients are evaluated for the presence of PSD using DSM-5 criteria ("gold standard"). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard.

No PSD
Patients NOT fulfilling DSM-5 criteria of PSD within 7 days of admission.
Diagnostic Test: Stroke screening tools
Patients are evaluated for the presence of PSD using DSM-5 criteria ("gold standard"). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard.




Primary Outcome Measures :
  1. diagnostic accuracy of established delirium detection tools as compared to Diagnostic and Statistical Manual - 5th Version (DSM-5) criteria [ Time Frame: two times daily for 7 days ]
    Binary outcomes of delirium screening tests will be compared, i.e. if they characterize an individual patient as delirious at any of two time points during the 7 day observation period. Instruments include: Nursing Delirium Screening Scale (Nu-DESC), Confusion Assessment Method (CAM), rapid assessment test for delirium (4-AT). Binary outcomes ("yes" or "no" according to each of the scales) are then aggregated in one test that compares the observed frequency of delirious patients (according the above mentioned tests) with the actual number of delirious patients as assessed by the DSM-5 standard.


Secondary Outcome Measures :
  1. PSD prevalence [ Time Frame: three times daily for 7 days ]
    DSM-5 criteria and chart review are used to assess the occurence of PSD among included patients over the complete study period

  2. pre-stroke modified Rankin Scale [ Time Frame: once on admission ]
    functional status before stroke

  3. pre-stroke Barthel Index [ Time Frame: once on admission ]
    ability to take care of personal daily routine before stroke

  4. pre-stroke Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) [ Time Frame: once on admission ]
    cognitive impairment before stroke

  5. pre-stroke Groningen Frailty Index (GFI) [ Time Frame: once on admission ]
    presence of a frailty syndrome before stroke

  6. National Institutes of Health Stroke Scale (NIHSS) [ Time Frame: three times daily for three days starting on the day of admission ]
    estimate of clinical stroke severity

  7. Critical Care Pain Observation Tool (CPOT) [ Time Frame: once daily for three days starting on the day of admission ]
    pain during stroke unit treatment

  8. Stroke location - clinical (classification of the OxfordshireCommunity Stroke Project (OCSP)) [ Time Frame: once on admission ]
    clinical characterisation based on phenotype as either total anterior, partial anterior, partial posterior or lacunar stroke

  9. Stroke location - imaging (based on an atlas of anatomical regions of the human brain (aal MNI V4)) [ Time Frame: once on admission ]
    in patients with imaging of the definite stroke location, differences of mean locations between groups will be calculated


Other Outcome Measures:
  1. demographic data [ Time Frame: once on admission ]
    exploratory outcome required to adjust for confounding variates such as age, socioeconomic status and education

  2. complications during stroke unit treatment [ Time Frame: continuously during the study period and up to 7 days ]
    any complication that arises during the study period (e.g. pneumonia, dysphagia)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Any patient admitted to the emergency department for a suspected ischemic cerebrovascular event is eligible to participate. A neurologist must then confirm the diagnosis and necessity for stroke unit monitoring.
Criteria

Inclusion Criteria:

  • stroke unit admission for a high-risk transient ischemic attack (ABCD2 score >= 6) or stroke within the last 24 hours

Exclusion Criteria:

  • hemorrhagic stroke

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03930719


Locations
Layout table for location information
Germany
Department of Neurology
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
Sponsors and Collaborators
University Medicine Greifswald
Investigators
Layout table for investigator information
Principal Investigator: Robert Fleischmann, MD Department of Neurology
Layout table for additonal information
Responsible Party: University Medicine Greifswald
ClinicalTrials.gov Identifier: NCT03930719    
Other Study ID Numbers: BB 031-19
First Posted: April 29, 2019    Key Record Dates
Last Update Posted: June 4, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Medicine Greifswald:
stroke
delirium
screening tool
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Delirium
Ischemic Attack, Transient
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Confusion
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
Neurocognitive Disorders
Mental Disorders
Brain Ischemia